United States 
Itzhak Perlman Headlines Great Neck Park District’s Summer Concert Series
5 days ago
David Fajgenbaum is a physician-scientist and author recognized for his pioneering research in rare diseases and drug repurposing, offering innovative solutions for various conditions.
David Fajgenbaum is an immunologist and co-founder of Every Cure, a nonprofit organization whose mission is to unlock the full potential of approved medicines through drug repurposing, utilizing AI to predict promising drug repurposing opportunities and validating them in clinical trials.
David Fajgenbaum is the Co-Founder and Executive Director of the Castleman Disease Collaborative Network, an organization created to research and identify effective treatments for Castleman disease.
Dr. Fajgenbaum serves on the Board of Directors for the Reagan-Udall Foundation for the FDA, contributing to efforts that support the FDA's public health mission.
Dr. David Fajgenbaum received a rare autoimmune and immunological disorder research grant at the Young Investigator Draft Presented by CSL Behring.
David Fajgenbaum received the Welcome Back Award for Community Service from Eli Lilly & National Council for Community Behavioral Healthcare.
David C. Fajgenbaum was born on March 29, 1985, in Raleigh, North Carolina. He pursued his undergraduate studies at Georgetown University, earning a BS in Honors Human Sciences with Distinction in 2007. During this time, he co-founded Actively Moving Forward to support grieving college students, following the loss of his mother to glioblastoma in 2004. He furthered his education with an MSc in Public Health from the University of Oxford in 2008, an MD from the University of Pennsylvania Perelman School of Medicine in 2013, and an MBA from The Wharton School at the University of Pennsylvania in 2015. While in medical school, Fajgenbaum became critically ill with idiopathic multicentric Castleman disease (iMCD), a rare and often fatal condition. This personal experience became a driving force behind his career.
Following his third relapse in 2012, Fajgenbaum co-founded the Castleman Disease Collaborative Network (CDCN) and dedicated himself to researching iMCD. He joined the Perelman School of Medicine of the University of Pennsylvania as an Assistant Professor of Medicine and Associate Director of the Orphan Disease Center in 2015, where he currently serves as an Associate Professor. He is also the founding director of the Center for Cytokine Storm Treatment & Laboratory (CSTL). His research led him to discover a repurposed treatment for his own iMCD, a story detailed in his national bestselling memoir, ‘Chasing My Cure: A Doctor’s Race to Turn Hope Into Action,’ which is being adapted into a film. Dr. Fajgenbaum has advanced a total of 14 repurposed treatments for cancers and rare diseases.
In 2022, he co-founded Every Cure, a nonprofit organization focused on leveraging artificial intelligence and computational pharmacophenomics to identify and validate new uses for existing medications. This initiative aims to accelerate the discovery of treatments for various diseases. Fajgenbaum has authored over 100 scientific papers in prominent journals, including The New England Journal of Medicine and The Lancet. He has received numerous accolades for his work, including the 2016 Atlas Award alongside then-VP Joe Biden, the 2022 NDRI Service to Science Award, and a selection to the 2025 TIME100 Health list. He also serves on the Board of Directors for the Reagan-Udall Foundation for the FDA.
Curious about our offerings or have inquiries? We're eager to assist!
Just complete the form, and we'll respond promptly.
